Budgetary impact of COPD treatment in II, III and IV with tiotropium versus ipratropium, in Spain
Section: Method
How to quote
Vinagre Romero JA, de Pablos Heredero C, Vicente Gabriel ML. Impacto presupuestario del tratamiento de la EPOC en estadios II, III y IV con tiotropio versus ipratropio en España. Metas de Enferm nov 2012; 15(9): 69-77
Authors
1José Antonio Vinagre Romero, 2Carmen de Pablos Heredero, 3Mª Luisa Vicente Gabriel
Position
1Supervisor de Enfermería del Centro de Especialidades Periféricas “José Marvá”, Hospital Universitario La Paz.
Contact address
José Antonio Vinagre Romero. Centro de Especialidades Periféricas José Marvá. Hospital Universitario “La Paz”. C/ Bravo Murillo, 317. 28020 Madrid.
Contact email: joseantonio.vinagre@salud.madrid.org
Abstract
Objective: to evaluate the budgetary impact of the approach of the pathology with tiotropium compared to ipratropium from the perspective of the National Health System (NHS), in conditions of optimal diagnosis and treatment of the disease and considering the intervening intermediate products.
Material and method: prospective descriptive study, with analytical intent, after implantation in the market (ex-post) of the therapeutic alternatives compared, carried out on the basis of previous studies, the costs of which, were adjusted by the current Consumer Price Index (CPI) within the field of health economics, in which a decision tree with three decisional branches was elaborated (moderate, severe and very severe stages of chronic obstructive pulmonary disease-COPD-). The analysis included direct healthcare costs of treatment in stable phase, treatment of exacerbations, and health resource utilization.
Results: treatment with tiotropium strategy had a financial repercussion on the last available figure of 2,7% of health spending, while the ipratropium strategy had a 1,5% repercussion. This showed a difference of 1,2% between strategies, which resulted in 841,1 million euros.
Conclusions: although the effectiveness of tiotropium results in lower probability of exacerbation, high costs dependent on the high price of the baseline treatment discourage it use compared to ipratropium, and therefore decreasing its cost-effectiveness.
Keywords:
budgetary impact; Chronic obstructive pulmonary disease (COPD); cost-effectiveness; drugs; ipratropium; research; tiotropiumtreatment replacement
Versión en Español
Título: